Meeting Intelligence

Strong quarterly review. Revenue up 12.4% YoY driven by Skyrizi formulary wins. Adherence nearing 90% target — SMS PDSA showing +4.9pp improvement. Capture rate at 68.4% remains below 75% target; prescriber engagement initiative proposed for Q3. Agreement to share formulary impact analysis and present PDSA study findings.

Critical remediation session. Capture rate at 48.2% — lowest in portfolio. Root cause: low prescriber awareness + 2 FTE staffing gap causing PA delays (38 hrs avg). Three remediation workstreams agreed: prescriber outreach, staffing hire, and eligibility screening deployment. All classified as urgent.

Portfolio health check: 3 of 5 clients on track. Onvida showing early improvement signals after remediation session. Michigan PA turnaround improving with electronic templates. Cigna step therapy for Skyrizi flagged as new risk — 120 patients affected. Q2 priorities confirmed: biosimilar conversion, Onvida recovery, Ascension QBR prep.

Review of PA fast-track PDSA progress. Electronic templates have reduced turnaround from 36 to 30 hours — need 6 more hours to hit 24-hr target. Staffing adjustments pending. Dr. Goldstein flagged that oncology PAs are the primary bottleneck — Cigna and Aetna denials requiring 2-3 rounds of clinical documentation.

Planning session for Phase 1 biosimilar conversion (Humira → Hadlima). 1,840 eligible patients across portfolio, only 620 converted so far (33.7%). Memorial Hermann and Ascension identified as best starting points due to prescriber buy-in. Payer formulary positions reviewed — UHC now mandating biosimilar for new starts.